[
  {
    "ts": null,
    "headline": "Citius Oncology Signs U.S. Distribution Agreement with McKesson to Support LYMPHIR™ Commercial Launch",
    "summary": "Citius Oncology, Inc. (\"Citius Oncology\") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. (\"Citius Pharma\") (Nasdaq: CTXR), today announced it has entered into a distribution services agreement with McKesson Corporation (NYSE: MCK), one of the largest pharmaceutical distributors and healthcare services companies in North America. Under the agreement, McKesson will serve as an authorized distributor of record for LYMPHIR (denileukin diftitox-cxdl), a novel immunoth",
    "url": "https://finnhub.io/api/news?id=1559607055954243f317bb302c44dffad1f945f44626657dc38f5394c402315b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760963820,
      "headline": "Citius Oncology Signs U.S. Distribution Agreement with McKesson to Support LYMPHIR™ Commercial Launch",
      "id": 137174510,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MCK",
      "source": "Yahoo",
      "summary": "Citius Oncology, Inc. (\"Citius Oncology\") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. (\"Citius Pharma\") (Nasdaq: CTXR), today announced it has entered into a distribution services agreement with McKesson Corporation (NYSE: MCK), one of the largest pharmaceutical distributors and healthcare services companies in North America. Under the agreement, McKesson will serve as an authorized distributor of record for LYMPHIR (denileukin diftitox-cxdl), a novel immunoth",
      "url": "https://finnhub.io/api/news?id=1559607055954243f317bb302c44dffad1f945f44626657dc38f5394c402315b"
    }
  }
]